+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peripheral Arterial Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Peripheral Arterial Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Peripheral Arterial Disease Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889014
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peripheral Arterial Disease Therapeutics Market is projected to reach USD 6.11 Billion in 2026. It is expected to continue growing at a CAGR of 9.08%, reaching USD 10.30 Billion by 2032.

Peripheral Arterial Disease Therapeutics: Executive Overview

Peripheral arterial disease (PAD) therapeutics address atherosclerotic narrowing of peripheral arteries, most often affecting the lower limbs. Treatment objectives include reducing cardiovascular and limb-related events, improving walking capacity, relieving symptoms, supporting wound healing, and preventing amputation. Clinical management typically combines risk-factor modification, antithrombotic therapy, lipid lowering, blood-pressure control, diabetes management, supervised exercise, symptom-directed medicines, and revascularization when indicated. The therapeutic context is shaped by aging populations, persistent cardiometabolic risk, smoking, limited diagnosis, and uneven access to vascular care.

PAD Care Is Shifting Toward Integrated, Limb-Preservation Pathways

The treatment landscape is moving from symptom control alone toward coordinated cardiovascular and limb-preservation pathways. Current practice increasingly emphasizes structured assessment of walking impairment, chronic limb-threatening ischemia, wound status, renal function, bleeding risk, and coexisting coronary or cerebrovascular disease. This shift supports earlier referral, multidisciplinary decision-making, alignment of medical therapy with endovascular or surgical options, and closer follow-up after intervention.
Additional transformation is coming from broader use of supervised exercise, home-based rehabilitation, smoking-cessation support, diabetes and lipid management, and standardized wound care. Guideline updates and real-world evidence continue to refine the balance between antithrombotic benefit and bleeding risk, particularly around revascularization. Persistent barriers include underdiagnosis, inconsistent ankle-brachial index use, fragmented care, and limited specialist capacity.

Artificial Intelligence Can Strengthen PAD Detection, Stratification, and Follow-Up

Artificial intelligence is accumulating across the PAD care pathway rather than replacing clinical judgment. Machine-learning models can help identify patients at elevated vascular risk from electronic health records, interpret vascular imaging and physiologic tests, prioritize abnormal findings, and support prediction of wound complications or recurrent events. Natural-language processing may also surface symptoms, smoking status, mobility limitations, and prior vascular history that are incompletely coded.
The greatest practical value is likely to come from workflow integration: prompting appropriate diagnostic testing, flagging high-risk patients for vascular review, supporting medication reconciliation, and monitoring adherence or functional change through remote tools. Safe adoption requires representative validation across sex, age, ethnicity, comorbidity, and care settings; transparent performance metrics; cybersecurity; clinician oversight; and prospective evaluation of whether algorithmic support improves outcomes without increasing unnecessary testing or treatment.

Regional Insights: Uneven Diagnosis and Access Shape Therapeutic Priorities

North America has comparatively developed vascular services and broad access to guideline-based prevention, yet obesity, diabetes, smoking, fragmented delivery, and disparities in specialist access remain important challenges. Latin America faces heterogeneous reimbursement, delayed diagnosis, and uneven availability of supervised exercise, advanced wound care, and revascularization, making primary prevention and referral coordination especially important. Europe benefits from established clinical guidance and multidisciplinary capacity in many countries, while variation in screening, waiting times, reimbursement, and access to newer antithrombotic strategies persists.
The Middle East is managing a growing cardiometabolic burden alongside differences in specialist infrastructure and prevention programs. Africa has a substantial need for earlier recognition, affordable essential medicines, diagnostic equipment, smoking cessation, diabetes care, and limb-preservation services, with urban-rural and public-private gaps particularly consequential. Asia-Pacific combines advanced vascular systems in several economies with major access constraints elsewhere; rapid aging, diabetes prevalence, smoking in some populations, and differences in health coverage make locally adapted care pathways essential.

Group Insights: Economic and Political Blocs Require Coordinated PAD Strategies

ASEAN countries show wide variation in health financing, diagnostic availability, specialist density, and urban-rural access, supporting regional efforts around essential medicines, referral protocols, and workforce development. BRICS members face large internal disparities but share opportunities to strengthen primary prevention, vascular diagnostics, diabetes control, and affordable limb-preservation services. The European Union can benefit from cross-border alignment in guideline implementation, outcomes measurement, procurement, and patient access while respecting national health-system structures.
G7 health systems generally have advanced clinical capabilities but must address aging, multimorbidity, care fragmentation, and inequities affecting underserved groups. GCC countries have invested in modern clinical infrastructure, while diabetes prevention, culturally appropriate lifestyle support, and continuity between primary and specialist care remain central priorities. NATO members span diverse health systems; preparedness, clinical interoperability, rehabilitation capacity, and continuity of essential vascular care are relevant to resilience, including during emergencies that disrupt routine treatment.

Country Insights: Local Epidemiology and Health-System Capacity Drive Priorities

Australia combines strong clinical capability with geographic access challenges, making telehealth, coordinated referral, and rural wound-care pathways valuable. Brazil and Mexico need to reduce delays in diagnosis and referral while expanding affordable prevention, diabetes management, vascular testing, and limb-preservation services. Canada and the United States have substantial specialist capacity, but rural access, racial and socioeconomic disparities, smoking cessation, and continuity across primary, vascular, and rehabilitation care remain important concerns.
China and India face large and diverse patient populations, substantial cardiometabolic risk, and marked variation between urban and rural services; scalable screening, affordable medicines, and coordinated referral are key priorities. Japan and South Korea must address aging, mobility decline, diabetes, and the integration of vascular prevention with long-term care. France, Germany, Italy, Spain, and the United Kingdom have established vascular pathways, but continued improvement is needed in timely diagnosis, rehabilitation, equitable access, post-revascularization follow-up, and consistent implementation of preventive therapy. Russia faces geographic and health-system variation, reinforcing the importance of primary-care detection, risk-factor control, and access to vascular expertise.

Actions for Leaders: Build Integrated, Measurable, and Equitable PAD Care

Industry leaders should prioritize solutions that fit coordinated care rather than isolated prescribing. Strengthen clinician education on ankle-brachial index use, symptom recognition, chronic limb-threatening ischemia, and antithrombotic risk assessment; support referral networks linking primary care, vascular specialists, podiatry, wound care, cardiology, diabetes services, and rehabilitation; and design patient programs that improve smoking cessation, medication persistence, exercise participation, and foot protection.
Evidence generation should reflect real-world diversity and report outcomes meaningful to patients, including walking ability, wound healing, hospitalization, amputation, bleeding, and quality of life. Digital and AI-enabled tools should be introduced with governance, bias testing, interoperability, and human review. Access strategies should account for affordability, rural delivery, public-sector procurement, diagnostic infrastructure, and culturally appropriate communication. Leaders should also monitor pathway metrics such as time to diagnosis, referral completion, preventive-treatment adherence, revascularization follow-up, and avoidable limb events.

Research Methodology: Evidence-Led Synthesis of PAD Therapeutic Priorities

This executive summary uses a structured narrative synthesis of established clinical concepts in peripheral arterial disease therapeutics, including disease burden drivers, treatment objectives, prevention, pharmacologic management, exercise and rehabilitation, wound care, revascularization, digital health, and health-system access. Regional, group, and country observations are framed around documented differences in demographic trends, cardiometabolic risk, healthcare infrastructure, clinical practice, reimbursement, and geographic access.
Interpretation should distinguish broadly established care principles from emerging applications, particularly artificial intelligence and remote monitoring. A rigorous full study would triangulate peer-reviewed literature, clinical guidelines, regulatory and health-policy documents, epidemiological surveillance, and real-world outcomes, with explicit source dates and assessment of study quality, external validity, confounding, and implementation context. No market estimates, market sizing, market shares, forecasts, or company-specific claims are used here.

Conclusion: Earlier Detection and Coordinated Prevention Are Central to PAD Outcomes

Peripheral arterial disease therapeutics are increasingly defined by integrated cardiovascular and limb-preservation care. The strongest clinical opportunity is not a single intervention, but timely recognition followed by sustained risk-factor control, evidence-based antithrombotic and lipid management, exercise and rehabilitation, vigilant foot and wound care, and appropriately selected revascularization. Artificial intelligence may improve identification and follow-up when validated and governed responsibly.
Progress will depend on adapting these principles to regional and national realities. Health systems and industry leaders should focus on reducing diagnostic delay, closing access gaps, measuring patient-centered outcomes, and building durable collaboration across primary care, vascular services, rehabilitation, and community settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Peripheral Arterial Disease Therapeutics Market, by Product Type
7.1. Introduction
7.2. Anticoagulants
7.2.1. Direct Oral Anticoagulants
7.2.2. Heparin
7.2.3. Warfarin
7.3. Antiplatelet Agents
7.3.1. Aspirin
7.3.2. Clopidogrel
7.3.3. Ticagrelor
7.4. Thrombolytics
7.4.1. Tissue Plasminogen Activator
7.4.2. Urokinase
7.5. Vasodilators
7.5.1. Cilostazol
7.5.2. Pentoxifylline
8. Peripheral Arterial Disease Therapeutics Market, by Indication
8.1. Introduction
8.2. Critical Limb Ischemia
8.3. Intermittent Claudication
9. Peripheral Arterial Disease Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
10. Peripheral Arterial Disease Therapeutics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Peripheral Arterial Disease Therapeutics Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Peripheral Arterial Disease Therapeutics Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Peripheral Arterial Disease Therapeutics Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Alucent Biomedical Inc.
15.3. AnGes, Inc.
15.4. AngioDynamics, Inc.
15.5. ARCA biopharma, Inc.
15.6. B. Braun SE
15.7. Becton, Dickinson and Company
15.8. BIOTRONIK SE & Co. KG
15.9. Boston Scientific Corporation
15.10. Cook Group Incorporated
15.11. Helixmith Co., Ltd.
15.12. Koninklijke Philips N.V.
15.13. LeMaitre Vascular, Inc.
15.14. Medtronic PLC
15.15. Meril Life Sciences Pvt. Ltd.
15.16. MicroPort Scientific Corporation
15.17. REVA Medical, LLC
15.18. Terumo Corporation
15.19. Venturis Therapeutics, Inc.
15.20. W. L. Gore & Associates, Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Peripheral Arterial Disease Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Peripheral Arterial Disease Therapeutics Market, Research Design
FIGURE 3. Global Peripheral Arterial Disease Therapeutics Market, Research Framework
FIGURE 4. Global Peripheral Arterial Disease Therapeutics Market, Data Triangulation
FIGURE 5. Global Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Peripheral Arterial Disease Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Peripheral Arterial Disease Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Peripheral Arterial Disease Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Peripheral Arterial Disease Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Peripheral Arterial Disease Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Peripheral Arterial Disease Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Peripheral Arterial Disease Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Peripheral Arterial Disease Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Peripheral Arterial Disease Therapeutics Market Segmentation & Coverage
TABLE 2. Global Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Anticoagulants Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Anticoagulants Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Anticoagulants Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Direct Oral Anticoagulants Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Direct Oral Anticoagulants Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Direct Oral Anticoagulants Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Heparin Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Heparin Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Heparin Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Warfarin Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Warfarin Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Warfarin Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Antiplatelet Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Antiplatelet Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Antiplatelet Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Aspirin Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Aspirin Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Aspirin Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Clopidogrel Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Clopidogrel Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Clopidogrel Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Ticagrelor Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Ticagrelor Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Ticagrelor Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Thrombolytics Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Thrombolytics Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Thrombolytics Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Tissue Plasminogen Activator Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Tissue Plasminogen Activator Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Tissue Plasminogen Activator Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Urokinase Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Urokinase Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Urokinase Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Vasodilators Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Vasodilators Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Vasodilators Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Cilostazol Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Cilostazol Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Cilostazol Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Pentoxifylline Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Pentoxifylline Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Pentoxifylline Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 47. Global Critical Limb Ischemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Critical Limb Ischemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Critical Limb Ischemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Intermittent Claudication Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Intermittent Claudication Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Intermittent Claudication Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 54. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Peripheral Arterial Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. North America Peripheral Arterial Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. North America Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 82. North America Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 83. North America Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 84. North America Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 85. North America Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 86. North America Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 87. North America Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 88. North America Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 92. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 93. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 94. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 95. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. Latin America Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 97. Latin America Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Europe Peripheral Arterial Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Europe Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 100. Europe Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 101. Europe Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 102. Europe Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 103. Europe Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 104. Europe Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 105. Europe Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 106. Europe Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 109. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 110. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 111. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 112. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 113. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. Middle East Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. Middle East Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. Africa Peripheral Arterial Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Africa Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 118. Africa Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 119. Africa Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 120. Africa Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 121. Africa Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 122. Africa Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. Africa Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 124. Africa Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Global Peripheral Arterial Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 128. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 129. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 130. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 131. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 132. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 133. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. ASEAN Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. GCC Peripheral Arterial Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. GCC Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. GCC Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 138. GCC Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 139. GCC Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 140. GCC Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 141. GCC Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. GCC Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 143. GCC Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. European Union Peripheral Arterial Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. European Union Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 146. European Union Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 147. European Union Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 148. European Union Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 149. European Union Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 150. European Union Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. European Union Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 152. European Union Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 155. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 156. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 157. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 158. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 159. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. BRICS Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. BRICS Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. G7 Peripheral Arterial Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. G7 Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 164. G7 Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 165. G7 Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 166. G7 Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 167. G7 Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 168. G7 Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 169. G7 Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 170. G7 Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. NATO Peripheral Arterial Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. NATO Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. NATO Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 174. NATO Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 175. NATO Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 176. NATO Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 177. NATO Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. NATO Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 179. NATO Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Global Peripheral Arterial Disease Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 181. United States Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 182. United States Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 183. United States Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 184. United States Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 185. United States Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 186. United States Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 187. United States Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. United States Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. United States Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Canada Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 191. Canada Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 192. Canada Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 193. Canada Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 194. Canada Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 195. Canada Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 196. Canada Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 197. Canada Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 198. Canada Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Mexico Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 200. Mexico Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. Mexico Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 202. Mexico Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 203. Mexico Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 204. Mexico Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 205. Mexico Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. Mexico Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. Mexico Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Brazil Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 209. Brazil Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 210. Brazil Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 211. Brazil Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 212. Brazil Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 213. Brazil Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 214. Brazil Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. Brazil Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 216. Brazil Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 218. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 220. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 221. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 222. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 223. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 225. United Kingdom Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. Germany Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 227. Germany Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 228. Germany Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 229. Germany Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 230. Germany Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 231. Germany Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 232. Germany Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. Germany Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 234. Germany Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. France Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 236. France Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 237. France Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 238. France Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 239. France Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 240. France Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 241. France Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. France Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. France Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Russia Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 245. Russia Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 246. Russia Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 247. Russia Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 248. Russia Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 249. Russia Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 250. Russia Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 251. Russia Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. Russia Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. Italy Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 254. Italy Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 255. Italy Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 256. Italy Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 257. Italy Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 258. Italy Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 259. Italy Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. Italy Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 261. Italy Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. Spain Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 263. Spain Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 264. Spain Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 265. Spain Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 266. Spain Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 267. Spain Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 268. Spain Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 269. Spain Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 270. Spain Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. China Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 272. China Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 273. China Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 274. China Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 275. China Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 276. China Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 277. China Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 278. China Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 279. China Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. India Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 281. India Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 282. India Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 283. India Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 284. India Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 285. India Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 286. India Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 287. India Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 288. India Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. Japan Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 290. Japan Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 291. Japan Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 292. Japan Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 293. Japan Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 294. Japan Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 295. Japan Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 296. Japan Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 297. Japan Peripheral Arterial Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. Australia Peripheral Arterial Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 299. Australia Peripheral Arterial Disease Therapeutics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 300. Australia Peripheral Arterial Disease Therapeutics Market Size, by Anticoagulants, 2017-2032 (USD Million)
TABLE 301. Australia Peripheral Arterial Disease Therapeutics Market Size, by Antiplatelet Agents, 2017-2032 (USD Million)
TABLE 302. Australia Peripheral Arterial Disease Therapeutics Market Size, by Thrombolytics, 2017-2032 (USD Million)
TABLE 303. Australia Peripheral Arterial Disease Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 304. Australia Peripheral Arterial Disease Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 305. Australia Peripheral Arterial Disease Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 306. Australia Peripheral Arterial Disease Thera

Companies Mentioned

  • Abbott Laboratories
  • Alucent Biomedical Inc.
  • AnGes, Inc.
  • AngioDynamics, Inc.
  • ARCA biopharma, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cook Group Incorporated
  • Helixmith Co., Ltd.
  • Koninklijke Philips N.V.
  • LeMaitre Vascular, Inc.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • REVA Medical, LLC
  • Terumo Corporation
  • Venturis Therapeutics, Inc.
  • W. L. Gore & Associates, Inc.

Related Topics

Related Reports

Peripheral Arterial Disease Market Report 2026 - Product Image

Peripheral Arterial Disease Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report - Product Image

Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report

  • Report
  • 188 Pages
  • Global
From
2025 Global Forecast for Peripheral Arterial Disease (Pad) Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Peripheral Arterial Disease (Pad) Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Critical Limb Ischemia - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Critical Limb Ischemia - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Catheter-Directed Thrombolysis Devices Market - Global Forecast 2026-2032 - Product Image

Catheter-Directed Thrombolysis Devices Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From

About the Peripheral Artery Disease Drug Market

Peripheral Artery Disease (PAD) is a cardiovascular disorder caused by the narrowing of arteries in the legs, leading to reduced blood flow and oxygen supply. PAD is a major cause of disability and death, and is often treated with drugs. Commonly prescribed drugs for PAD include antiplatelet agents, anticoagulants, statins, and vasodilators. Antiplatelet agents reduce the risk of blood clots, while anticoagulants prevent the formation of clots. Statins are used to reduce cholesterol levels, while vasodilators widen the arteries and improve blood flow. The PAD drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of PAD, the development of new drugs, and the rising demand for better treatments. The market is expected to grow at a steady rate in the coming years, driven by the increasing prevalence of PAD and the development of new drugs. Some of the major companies in the PAD drug market include Pfizer, Merck, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.